SAN FRANCISCO, Oct. 10 – Incyte Genomics has enter a licensing and development alliance with molecular tools manufacturer Epoch Biosciences, the companies announced Wednesday.
The terms include Epoch’s licensing Palo Alto-based Incyte’s LifeSeq Gold and ZooSeq databases for development of oligonucleotide probes and Incyte naming Epoch the “preferred provider” of custom oligonucleotide probes in addition to receiving Epoch Eclipse Probe Systems for use in internal development.
Financial details of the agreement were not disclosed.
“Epoch is recognized for its leading technologies related to the development of enhanced genetic analysis tools,” Roy A. Whitfield, CEO of Incyte, said in a statement. “This alliance with Epoch leverages their probe design and manufacturing capabilities and provides our users of LifeSeq Gold with a source of reliable probes to enhance their genetic analysis and research efforts.”
Epoch Biosciences is based in Bothell, Wash.